VBWG
Meeting report

ExTRACT-TIMI 25 study

Results from ExTRACT-TIMI 25: The Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis in Myocardial Infarction Study 25




ExTRACT-TIMI 25

Download VBWG06_ExTRACT_TIMI.ppt (14 slides - 0.7MB)

ExTRACT-TIMI 25 ExTRACT-TIMI 25: Background ExTRACT-TIMI 25: Study design ExTRACT-TIMI 25: Medical history and prior treatments ExTRACT-TIMI 25: Baseline characteristics ExTRACT-TIMI 25: Baseline treatment ExTRACT-TIMI 25: Cardiac medications during hospitalization ExTRACT-TIMI 25: Significant reduction in primary end point ExTRACT-TIMI 25: Significant reduction in major secondary end point ExTRACT-TIMI 25: Safety outcomes at 30 days ExTRACT-TIMI 25: Net clinical benefit at 30 days ExTRACT-TIMI 25: Overall results ExTRACT-TIMI 25: Summary ExTRACT-TIMI 25: Clinical implications


EnoxaparinExTRACTinfarctionMyocardialReperfusionThrombolysisTIMI

Related at vwbg.org

Decrease in PAI-1 antigen is greater with ACE inhibition

Plasminogen activator inhibitor-1 (PAI-1) is a known risk factor for cardiovascular (CV) disease and myocardial infarction (MI).

RITA 3: Benefit of early invasive strategy in moderate-risk unstable angina patients

Final results of RITA 3 (Randomized Intervention Trial of unstable Angina) confirm that an interventional strategy results in a statistically significant reduction in the combined outcome of death, nonfatal myocardial infarction (MI), or refractory angina.

Core Curriculum

Myocardial Ischemia Redefined: Optimal Care in CAD

View/Download individual slides (90 Slides)
More related